An adult with suspected ADHD researching clinics has questions that no generic chatbot can answer. Do you do telehealth in Texas after the post-COVID rules changed. Will you prescribe Adderall on the first visit or only after a separate evaluation. How does Vyvanse versus Concerta dosing get adjusted, and how often are follow-ups. What does the QbCheck or TOVA cost out of pocket. Each of these answers varies by state, by clinic, and by prescriber. None of them are guessable.

SleekAI maps the real policy to WordPress data. Prescribers live in a prescriber post type with ACF fields for state licenses, telehealth platforms (Doxy, SimplePractice, Spruce), controlled-substance prescribing policy (first-visit, second-visit, never), and refill cadence (28-day, 30-day, 90-day for non-stimulant). State law nuances sit in postmeta keyed by state. The bot reads wp_posts and wp_postmeta at request time, so a patient in Florida gets Florida-specific answers and a patient in California gets California-specific answers.

Generic chatbots default to general DEA guidance and end up wrong about your specific clinic. They might say telehealth controlled-substance prescribing requires an in-person visit, when in fact the DEA extended the flexibilities through 2026 with conditions. They will not know that you require a baseline ECG for patients over 50 on stimulants. SleekAI does, because it is reading the row your medical director maintains.

ADHD treatment sits at the intersection of state licensing law, DEA scheduling rules, telehealth flexibility extensions, and ordinary clinical practice. A generic chatbot trained on the open internet will be confidently wrong about all four. The DEA's special registration for telehealth controlled-substance prescribing has been delayed and extended multiple times, and the rules differ by state.

Most patients researching ADHD treatment do not know the difference between Schedule II and Schedule IV medications, and they do not need to, but they do need to know if your clinic can see them remotely in their state and how often they will need to check in for refills. SleekAI gets those answers right because it is reading the clinic's own policy as data, not guessing from training. The bot also handles the awkward middle of the conversation: adults who suspect they have ADHD have read confusing things online about stimulant access, and many are wary of being judged as drug-seeking.

A calm, clear explanation of your evaluation pathway and second-visit prescribing policy sets expectations honestly. Patients who would not be a good fit (people in unlicensed states, people seeking a same-day prescription without an eval) get a clean answer instead of an intake call that wastes everyone's time. Patients who are a good fit arrive at the eval already understanding the process, the rhythm of follow-ups, and what their insurance will cover.

Conversion improves, no-show rates drop, and your intake coordinator stops being the front-line educator for DEA policy.